|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
Synthetix (SNX) to Re-Acquire Crypto Options Platform Derive
May 14, 2025 at 02:14 pm

Synthetix, the decentralized finance platform, is planning to venture further into crypto derivatives with plans to re-acquire the crypto options platform Derive.
Synthetix said in a May 14 blog post that it plans to acquire Derive in a token exchange deal, pricing 1 SNX token to 27 DRV tokens, which would value Derive at around $27 million.
The transaction is subject to approval from both the Synthetix and Derive communities, which will take a vote on the proposal, called SIP-415, next week.
If approved, the acquisition will combine Derive’s front-end and real-world asset (RWA) expertise with Synthetix’s derivatives infrastructure.
Derive originally launched as Lyra in 2021, having spun out from the Synthetix ecosystem. Synthetix said the acquisition is part of a broader strategy that includes recent acquisitions of Kwenta and TLX, reflecting ecosystem consolidation.
“Reuniting under one banner simplifies our architecture and governance and unlocks the next phase of what we can achieve together. This is the kids going out to build their own successful startups, and coming back to join the family business.”
“This re-acquisition marks the next chapter of vertical reintegration with direct protocol ownership of perps, options, and app chains: all of which already have SNX in their DNA.”
The announcement names Hyperliquid, Binance, dYdX, and Deribit, which will be acquired by Coinbase, as competitors, highlighting Synthetix’s ambitions to rival major crypto derivatives platforms.
SNX token mint and lockup
To facilitate the acquisition, Ethereum-based Synthetix will issue up to 29.3 million of its self-titled Synthetix (SNX) token with a three-month lock-up followed by a nine-month linear vesting.
SNX has gained 11.5% on the day to reach $0.94 at the time of writing.
However, like most altcoins, it is massively down from its peak and is down almost 97% from its all-time high of $28.53 in February 2021, according to CoinGecko.
Synthetix has also suffered recently as its native stablecoin, sUSD, depegged and fell to a low of $0.68 on April 18. The dollar-pegged asset remains below its peg at $0.93 at the time of writing.
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
-
- Datavecta Forges Global Community Ecosystem to Power International Growth Through Advanced SEO Strategy
- Sep 30, 2026 at 07:55 pm
- Datavecta is building a global community ecosystem to enhance international growth, leveraging advanced SEO strategies and technology-driven services for a connected intelligent trading future.
-
- Illinois Rolls Out Draft Rules for 0.2% Crypto Transaction Tax, Set for 2027
- Sep 30, 2026 at 12:05 pm
- Illinois unveils draft regulations for its upcoming 0.2% digital asset transaction tax, impacting exchanges, transfers, and custody services starting January 1, 2027. The tax applies to the gross value of transactions, not investment gains.
-
-
- Apeing Leads the Charge: Unveiling the Next 100x Crypto Watchlist and 6 Coins to Eye
- Sep 30, 2026 at 12:03 pm
- Amidst a dynamic crypto market, Apeing's presale momentum, coupled with established players like Solana and TRON, is redefining the 100x crypto narrative, offering both early-stage opportunities and proven network strength.
-
-
- OpenAI Unveils GPT-6.1 Sol and Ultrafast Tier, While AstraZeneca Invests Big in Summit Therapeutics
- Sep 30, 2026 at 08:05 am
- OpenAI rolls out GPT-6.1 Sol, offering near-Astra performance at a fraction of the cost, alongside a new 'Ultrafast' speed tier. Meanwhile, AstraZeneca makes a significant $2 billion investment in oncology firm Summit Therapeutics.
-
-
































